Copanlisib for the treatment of adults with relapsed follicular lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Copanlisib for the treatment of adults with relapsed follicular lymphoma
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2020-06-24
DOI
10.1080/17512433.2020.1787829
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
- (2019) Matthew J. Matasar et al. ONCOLOGIST
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
- (2019) N. Nora Bennani et al. BLOOD
- Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
- (2019) Changying Jiang et al. BLOOD
- Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)
- (2019) Christian Grommes et al. BLOOD
- Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies
- (2019) Pier Luigi Zinzani et al. BLOOD
- Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
- (2019) Stefan K. Barta et al. BLOOD
- Targeting AKT for cancer therapy
- (2019) Maryam Shariati et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
- (2019) Franck Morschhauser et al. MOLECULAR CANCER THERAPEUTICS
- Follicular lymphoma: 2018 update on diagnosis and management
- (2018) Arnold Freedman AMERICAN JOURNAL OF HEMATOLOGY
- Pathogenesis of follicular lymphoma
- (2018) Tracy Lackraj et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Treatment of localized-stage follicular lymphoma
- (2018) Marc Sorigue et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort
- (2018) Lisa M. Rimsza et al. HAEMATOLOGICA
- Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
- (2018) Stefano Luminari et al. JOURNAL OF CLINICAL ONCOLOGY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort
- (2018) Lisa M. Rimsza et al. HAEMATOLOGICA
- Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
- (2018) Felix Mensah et al. OncoTargets and Therapy
- Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
- (2018) Günter Krause et al. Drug Design Development and Therapy
- Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
- (2018) Bruce D. Cheson et al. Clinical Lymphoma Myeloma & Leukemia
- PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
- (2017) Benjamin L. Lampson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- SAFETY RUN-IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA
- (2017) J. Gerecitano et al. HEMATOLOGICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- Follicular lymphoma: evolving therapeutic strategies
- (2016) B. S. Kahl et al. BLOOD
- Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- (2016) David Rizzieri CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date
- (2016) Till Seiler et al. DRUGS
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Life expectancy of young adults with follicular lymphoma
- (2015) A. Conconi et al. ANNALS OF ONCOLOGY
- Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma
- (2014) Wenli Cui et al. Journal of Translational Medicine
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
- (2014) Kirit M Ardeshna et al. LANCET ONCOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) M. Dreyling et al. ANNALS OF ONCOLOGY
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
- (2009) Lakshmi Srinivasan et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation